 64th Annual Conference
Thursday, March 8
Early Bird Open Sessions
7:15-8:15 A.M.
Session 204
Psychopharmacology for Group Therapists
Presenter:
David Brook,
M.D., CGP, FAGPA,
Professor of Psychiatry, New York University School of Medicine, New
York, New York
Many patients in group therapy
also take a variety of CNS medications. This open session will
review the essentials of psychopharmacological treatments as related
to their uses in group psychotherapy. Current issues and research
findings regarding the neurobiology and clinical uses of the major
classes of psychopharmacological drugs for the treatment of a
variety of psychiatric disorders in conjunction with group
psychotherapy will be discussed. Clinical examples brought up by the
presenter and by the participants will be used to illustrate the
material presented.
Learning Objectives:
T he
attendee will be able to:
1. Understand the ways and mechanisms of action in which the major
classes of psychopharmacological treatments can be used as adjuncts
to group psychotherapy.
2. Assess the appropriate uses
and choices of psychopharmacological treatments for a variety of
psychiatric disorders treated by group psychotherapists in a variety
of treatment settings.
3. Gain an overview of
neurobiological processes with regard to the use of CNS medications
and their clinical implications for group psychotherapeutic
treatments.
Course References:
1. Lauriello, J., Lenroot, R.,
Bustillo, J. (2003). Maximizing the Synergy Between
Pharmacotherapy and Psychosocial Therapies for Schizophrenia.
Psychiatric Clinics of North America. 26 (1): 191-211.
2. Hollon, S., Jarrett, R.,
Nierenberg, A., Thase, M., Trivedi, M., Rush, A. (2005).
Psychotherapy and Medication in the Treatment of Adult and Geriatric
Depression: Which monotherapy or combined treatment? Journal of
Clinical Psychiatry. 66 (4): 455-468.
3. Brook, D. (1993). Medication
Groups. In A. Alonso and H. Swiller. (Eds.).
Group Therapy in
Clinical Practice. Washington, D.C.: American Psychiatric Press,
Inc. 155-170. |
